Abstract
Neuropsychiatric symptoms (NPS) including behavioral and psychiatric symptoms are common in the dementia stages of Alzheimer's disease (AD) and are associated with poorer outcomes in cognition, functional states, quality of life, and accelerated progression to severe dementia or death. NPS are also increasingly observed in the mild cognitive impairment stage of AD and may predict incipient dementia. As such, there is an emerging conceptual framework, which support NPS as early non-cognitive symptoms of dementia. [<sup>18</sup>F]fluorodeoxyglucose positron emission tomography (FDG-PET) is a technique that is sensitive in detecting resting metabolism associated with NPS in neuropsychiatric conditions, and there is a growing body of literature evaluating the role of NPS as early indicators of brain metabolic dysfunctions in AD. In this mini-review, we examine the frequency and associations of NPS with metabolic dysfunction in the AD continuum, including preclinical, prodromal, and dementia stages of AD. We will also present the validated neurobehavioral syndrome, mild behavioral impairment (MBI), which describes the later life emergence of sustained NPS as an at-risk state for incident cognitive decline and dementia. Lastly, we will discuss future directions in the field to better understand the neurobiological basis of NPS in the early stages of the AD continuum and their role in predicting AD pathophysiological progression.
Introduction
Traditionally, Alzheimer’s Disease (AD) research has centered on cognitive decline, specifically memory and logic. However, non-cognitive neuropsychiatric symptoms (NPS)—such as apathy, anxiety, and agitation—are remarkably prevalent, affecting up to 75% of patients even during the Mild Cognitive Impairment (MCI) stage. These symptoms are frequently misidentified as primary psychiatric disorders or dismissed as normal aging. This review addresses the critical need to establish the neurobiological basis of NPS, linking specific behaviors to measurable metabolic dysfunction in the brain to improve early diagnosis and intervention strategies.
Methodology
The authors conducted a systematic literature search via PubMed (up to January 2019), filtering over 5,000 articles to identify 17 core studies. These studies utilized FDG-PET to measure the cerebral glucose metabolic rate (CMRglc) in relation to NPS across the AD continuum (preclinical, prodromal/MCI, and dementia). FDG-PET serves as a proxy for neuronal and synaptic activity, where reduced glucose uptake (hypometabolism) indicates underlying neuronal dysfunction. Data were synthesized from major longitudinal studies including the Alzheimer’s Disease Neuroimaging Initiative (ADNI), the Dominantly Inherited Alzheimer Network (DIAN), and the Mayo Clinic Study of Aging.
Mapping Behavioral Symptoms to Metabolic Networks
NPS are not random occurrences but map to specific functional brain networks. Research indicates that apathy is closely linked to the Default Mode Network (DMN), particularly hypometabolism in the posterior cingulate cortex (PCC). Conversely, hyperactivity and agitation are associated with the Salience Network (SN), involving the anterior cingulate cortex (ACC) and insula.
An interesting finding is the "hypermetabolism paradox" in early-stage depression and anxiety, where some studies showed increased metabolism in frontal regions. This may represent a compensatory mechanism or aberrant signaling before eventual neuronal failure. Furthermore, delusions in AD appear strongly linked to metabolic dysfunction in the right frontal and temporal lobes, suggesting a breakdown in reality-testing circuitry.
Clinical Significance in Early Stages
NPS are found in 35%–75% of MCI patients, with depression appearing in approximately 32% of cases. In cognitively normal individuals, the presence of NPS significantly increases the risk of progressing to MCI or dementia within five years. Apathy, in particular, correlates with an "AD-like" pattern of hypometabolism in the PCC, making it a strong metabolic proxy for early AD pathology.
The emergence of the Mild Behavioral Impairment (MBI) framework provides a validated syndrome for late-life sustained NPS as a high-risk state. Using the MBI-C checklist, researchers found a prevalence of ~14.2% in MCI populations, offering a more specific "enriched" group for clinical trials than cognitive testing alone.
Conclusion and Future Directions
While the link between NPS and metabolic dysfunction is evident, several challenges remain. There is a lack of FDG-PET data on "preclinical" (asymptomatic) individuals. Distinguishing between lifelong psychiatric history and early AD-related NPS is also difficult. Future research should integrate multi-modal imaging, combining FDG-PET with Amyloid and Tau PET, and utilize standardized tools like the MBI-C to harmonize global research efforts. Understanding these neurobiological underpinnings is essential for predicting AD progression and developing targeted therapies.
Summary updated